Wolverine Trading’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $2.79M | Buy |
47,400
+2,000
| +4% | +$66.2K | ﹤0.01% | 1882 |
|
|
2025
Q2 | $1.17M | Buy |
45,400
+44,253
| +3,858% | +$497K | ﹤0.01% | 2161 |
|
|
2025
Q1 | $12.7K | Buy |
+1,147
| New | +$15K | ﹤0.01% | 4595 |
|
|
2023
Q3 | – | Sell |
-780
| Closed | -$6.74K | – | 4895 |
|
|
2023
Q2 | $6.74K | Buy |
+780
| New | +$8.32K | ﹤0.01% | 4150 |
|
|
2022
Q4 | – | Sell |
-1,673
| Closed | -$76K | – | 4687 |
|
|
2022
Q3 | $76K | Buy |
1,673
+146
| +10% | +$8.69K | ﹤0.01% | 4018 |
|
|
2022
Q2 | $91K | Sell |
1,527
-1,006
| -40% | -$63.5K | ﹤0.01% | 3874 |
|
|
2022
Q1 | $212K | Buy |
2,533
+286
| +13% | +$42.3K | ﹤0.01% | 4346 |
|
|
2021
Q4 | $472K | Sell |
2,247
-1,513
| -40% | -$328K | ﹤0.01% | 3537 |
|
|
2021
Q3 | $1.01M | Buy |
3,760
+2,447
| +186% | +$588K | ﹤0.01% | 2968 |
|
|
2021
Q2 | $343K | Sell |
1,313
-107
| -8% | -$29.6K | ﹤0.01% | 4230 |
|
|
2021
Q1 | $416K | Sell |
1,420
-2,507
| -64% | -$780K | ﹤0.01% | 3988 |
|
|
2020
Q4 | $1.06M | Buy |
3,927
+860
| +28% | +$222K | ﹤0.01% | 2311 |
|
|
2020
Q3 | $777K | Sell |
3,067
-80
| -3% | -$25.2K | ﹤0.01% | 2326 |
|
|
2020
Q2 | $1.06M | Buy |
3,147
+1,714
| +120% | +$535K | ﹤0.01% | 1948 |
|
|
2020
Q1 | $388K | Sell |
1,433
-2,467
| -63% | -$763K | ﹤0.01% | 2931 |
|
|
2019
Q4 | $1.22M | Buy |
3,900
+1,287
| +49% | +$373K | ﹤0.01% | 2233 |
|
|
2019
Q3 | $702K | Buy |
2,613
+926
| +55% | +$340K | ﹤0.01% | 2277 |
|
|
2019
Q2 | $900K | Buy |
1,687
+247
| +17% | +$124K | ﹤0.01% | 2147 |
|
|
2019
Q1 | $726K | Sell |
1,440
-1,780
| -55% | -$1.05M | ﹤0.01% | 2381 |
|
|
2018
Q4 | $1.62M | Sell |
3,220
-913
| -22% | -$551K | ﹤0.01% | 1580 |
|
|
2018
Q3 | $3.78M | Buy |
4,133
+626
| +18% | +$534K | 0.01% | 1168 |
|
|
2018
Q2 | $5.59M | Hold |
3,507
| – | – | 0.01% | 792 |
|
|
2018
Q1 | $5.59M | Buy |
3,507
+154
| +5% | +$198K | 0.01% | 792 |
|
|
2017
Q4 | $3M | Sell |
3,353
-1,194
| -26% | -$706K | 0.01% | 1217 |
|
|
2017
Q3 | $1.64M | Buy |
4,547
+580
| +15% | +$181K | 0.01% | 1478 |
|
|
2017
Q2 | $1.15M | Buy |
+3,967
| New | +$1.15M | 0.01% | 1631 |
|
|
2017
Q1 | – | Sell |
-3,033
| Closed | -$558K | – | 4756 |
|
|
2016
Q4 | $558K | Buy |
3,033
+1,026
| +51% | +$209K | ﹤0.01% | 2499 |
|
|
2016
Q3 | $510K | Sell |
2,007
-333
| -14% | -$85.7K | ﹤0.01% | 2555 |
|
|
2016
Q2 | $490K | Buy |
+2,340
| New | +$523K | ﹤0.01% | 2247 |
|
Other funds holding NKTR
BI
FCM
NCM
Wolverine Trading's NKTR Position: Q3 2025 in Review
Wolverine Trading increased its Nektar Therapeutics (NKTR) stake by 283% in Q3 2025, buying an estimated $1.41M and bringing the position to 57,758 shares worth $3.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1716.
Wolverine Trading first reported a position in NKTR in Q3 2016 and has held it in 20 quarters since. 154 funds tracked by Wall St. Rank hold NKTR as of Q3 2025.
- Wolverine Trading held 57,758 shares of Nektar Therapeutics worth $3.4M as of Q3 2025.
- Wolverine Trading bought 42,686 Nektar Therapeutics shares in Q3 2025, an estimated $1.41M.
- Nektar Therapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #1716 holding.
- Wolverine Trading first reported a position in Nektar Therapeutics in Q3 2016 and has held it in 20 quarters since.
- 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.